AC Immune Advances in Alzheimer’s Trial, Secures Funding
Company Announcements

AC Immune Advances in Alzheimer’s Trial, Secures Funding

AC Immune SA (ACIU) has released an update.

AC Immune SA announced receiving a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, marking progress in the Phase 2b Re𝜏ain trial of its Alzheimer’s treatment, ACI-35.030. The payment was triggered by a swift prescreening rate for the trial, which aims to enroll around 500 pre-symptomatic Alzheimer’s patients and has already garnered a total of CHF 40 million in milestone payments. Highlighting the potential of its active immunotherapy candidate and robust financial position, AC Immune anticipates reaching transformative milestones within its three-year operational cash runway.

For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAC Immune SA Reports Profitable Q3 2024 Results
TheFlyAC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year
TipRanks Auto-Generated NewsdeskAC Immune SA Welcomes New CMO Dr. Anke Post
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App